Saturday, April 26, 2025 4/26/2025

A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection

Award Number: R01AI154561
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection - PROJECT SUMMARY Pre-exposure prophylaxis (PrEP) using orally or topically delivered antiretroviral (ARV) drugs can prevent HIV infection in susceptible, uninfected individuals. Adherence to the daily or monthly dosing regimens, however, has emerged as a critical factor driving the clinical success of HIV PrEP. The poor adherence of some participant groups in the ASPIRE trial of an intravaginal ring (IVR) delivering the non-nucleoside reverse transcriptase inhibitor (NNRTI) dapivirine (DPV) indicates that multiple barriers to adherence exist, and strategies beyond decreased dosing frequency will be required for successful implementation of an effective non-vaccine, method to prevent HIV infection. “Long-acting” subdermal implant ARV formulations that maintain protection for periods of 6 months, and preferably 1 year, or more may increase adherence by minimizing a product's use demands once the initial product uptake decision is made. We propose a resorbable subdermal implant Sustained/Extended Release Drug Delivery System (SER-DDS) delivering a novel ARV agent from the maturation inhibitor mechanistic class. The implant will be developed through a three-tiered formulation development process employing design, fabrication, and in vitro studies iteratively coupled with in vivo PK, degradation, safety, and efficacy studies in three animal models. The drug is DFH-1160005, a novel betulin-derived, 2nd generation maturation inhibitor (MI) with single-digit nanomolar potency against HIV and a robust resistance profile. The program objectives are to develop a safe and effective SER-DDS for HIV prevention; understand the fundamental pharmacology of sustained, systemic DFH-1160005 delivery in the context of vaginal and rectal HIV infection, and apply rigorous methodologies to characterize implant degradation and evaluate safety and efficacy in preclinical in vivo models. In Aim 1, we will formulate implants, measure drug release in vitro, and conduct PK studies in rats, sheep, and rhesus macaques. In Aim 2, we will investigate SER-DDS degradation and resorption kinetics and mechanisms in vitro and in vivo. In Aim 3, we will evaluate lead candidate SER-DDS safety in sheep and explore efficacy and PK- pharmacodynamic relationships in a non-human primate rectal and vaginal challenge SHIV infection model.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $886,859 )
2024	2024	OAK CREST INSTITUTE OF SCIENCE	132 W CHESTNUT AVE	MONROVIA	CA	91016	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	5	7/5/2024	NON-COMPETING CONTINUATION	$886,859
														Subtotal = $886,859

Issue Date FY: 2023 ( Subtotal = $890,560 )
2023	2023	OAK CREST INSTITUTE OF SCIENCE	132 W CHESTNUT AVE	MONROVIA	CA	91016	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	4	7/21/2023	NON-COMPETING CONTINUATION	$890,560
														Subtotal = $890,560

Issue Date FY: 2022 ( Subtotal = $904,172 )
2022	2022	OAK CREST INSTITUTE OF SCIENCE	132 W CHESTNUT AVE	MONROVIA	CA	91016	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	7/20/2022	NON-COMPETING CONTINUATION	$904,172
														Subtotal = $904,172

Issue Date FY: 2021 ( Subtotal = $877,357 )
2021	2021	OAK CREST INSTITUTE OF SCIENCE	132 W CHESTNUT AVE	MONROVIA	CA	91016	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	2	7/29/2021	NON-COMPETING CONTINUATION	$877,357
														Subtotal = $877,357

Issue Date FY: 2020 ( Subtotal = $914,204 )
2020	2020	OAK CREST INSTITUTE OF SCIENCE	132 W CHESTNUT AVE	MONROVIA	CA	91016	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	1	8/28/2020	NEW	$914,204
														Subtotal = $914,204

Grand Total All Awards = $4,473,152

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection

Award Number: R01AI154561

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer